Technology Overview: A plasmid DNA vaccine that
encodes a secreted form of non-structural protein 1
(secNS1). It is highly immunogenic and offers complete
systemic protection from Zika in vaccinated mice. The
vaccine protects and completely eliminates ZIKA virus in
preclinical studies. We have modified the plasmid DNA
vaccine to include a leader sequence upstream of the NS1
gene, resulting in secretion of NS1 from vaccinetransfected
cells) – similar to what happens with NS1
during natural Zika infection in humans. The
immunogenic portion of the sequence elicits various
responses including T-helper response, a cytotoxic-T-cell
response, and/or a B-cell response.
Potential Applications: A vaccine that protects and
eliminates ZIKA virus and has the potential to treat or
reduce transmission of Zika virus infection and to block
transmission of Zika in mosquitoes. Additionally, the
technology provides a tool for detecting Zika infection.
Key Features & Benefits: A simple and intensive DNA
vaccine that elicits robust humoral and cell mediated
immune response to the Zika virus NS1 protein, resulting
in protection against challenge. Key features include:
• No need for adjuvant
• Stable for transportation and storage
• Synthesizes a specific antigen response
• No risk of ADE
• Low reactogenicity (candidate for pregnant women)
• No vector immunity: prime – boost
• Excellent safety profile
Detailed briefing document can be found here.